You are here: Industry Insights > RA

News List

Healthy Lifestyle Cuts Rheumatoid Arthritis Risk drugs.com
February 07, 2022
A healthier lifestyle is associated with lower rheumatoid arthritis (RA) risk, according to a study published online Jan. 18 in Arthritis Care & Research.
Serum Biomarkers Can Differentiate Psoriatic Arthritis, RA drugs.com
December 21, 2021
A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA), according to a study recently published in Arthritis & Rheumatology.
App to Monitor RA Symptoms Does Not Improve Disease Outcomes drugs
June 24, 2021
Use of a smartphone application (app) to monitor patient-reported outcomes does not improve satisfaction or disease outcomes in rheumatoid RA, but patients are likely to recommend the app, according to a study recently published in Arthritis &Rheumatology
Imcyse, Pfizer Enter Autoimmune Research Alliance contractpharma
February 04, 2021
Imcyse has entered into a research collaboration and license agreement with Pfizer Inc. for Imcyse's Rheumatoid Arthritis (RA) program based on the company's Imotope technology.
Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib) expresspharma
December 16, 2020
Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties on European sales starting in 2024.
Subcutaneous Remsima launched in UK pharmatimes
March 06, 2020
Celltrion has announced the launch of its subcutaneous Remsima (infliximab) formulation, offering a new treatment option for UK physicians and their patients.
Adherence to Ideal Pathway in Pregnancy Reduces Risks in RA drugs
January 20, 2020
For women with rheumatoid arthritis (RA), adherence to an ideal clinical pathway during pregnancy is associated with a reduced risk for miscarriage and complicated birth, according to a study published online January in Arthritis Care & Research.
Depression May Worsen QOL in Rheumatoid Arthritis Patients drugs
December 30, 2019
Patients with coexisting rheumatoid arthritis (RA) and depression tend to have higher disease activity and lower quality of life than patients without depression ...
Gilead Submits Filgotinib NDA for Rheumatoid Arthritis Treatment americanpharmaceuticalreview
December 24, 2019
Gilead Sciences has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the ...
Gilead Sciences submits NDA to treat RA in Japan biospectrumasia
October 10, 2019
Gilead Sciences, Inc. has announced the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis (RA) has been submitted to the Japanese Ministry of Health, Labor a

Previous page 1 2 Next page